Growth of Global Peptides and Heparin Market Poised for Rapid Surge at a CAGR of 8.10% by 2026

Posted on 2018-07-05 by Mark Hub in Healthcare // 0 Comments

ROCKVILLE, US, 2018-Jul-05 — /EPR Network/ — Peptides are amino acids’ short chains connected through peptide bonds. Peptides are molecules that are commonly known as proteins, whose functions are determined on the basis of the amino acid sequence and size. Heparin is known as disaccharide anticoagulant, commonly referred to as blood thinner, which prevents formation of blood clots. Mast cells and basophils in a body produce heparin, which is stored in mast cells and secreted wherever injuries occur.

A new report by Fact.MR projects the global market for peptide and heparin to reflect an impressive expansion during the forecast period, 2017 to 2026. Revenues from the market are estimated to exceed US$ 34,000 Mn by 2026-end.

Request For Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=378

The scope of FactMR’s report is to analyze the global peptide and heparin market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global peptide and heparin market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide and heparin.

Drug Developers Shifting Back to Peptides owing to Mounting Challenges regarding Small Molecules

While the pharmaceutical sector discerned small molecules as the medicinal agents, therapeutic peptides were considered to be niche products. However, with mounting challenges regarding small molecules, drug developers are shifting their concentration back to small amino acid chains. Although peptides have been deemed ineffective for developing drugs, modern peptide drug designs and formulations have been developed for circumventing their weaknesses. For example, original requirement for injecting peptides such as insulin is fading, with more patient-friendly administrations progressively being developed. In addition, the current society that critically judges undesirable effects and environmental impact of the candidate medicines is embracing the safety offered by peptides.

Heparin is being extensively employed as an antitumor and anti-inflammatory agent. The anti-inflammatory characteristic of heparin, which prevents metastatic spreading of tumor cells, is a new research finding among healthcare professionals. The metastatic spreading of tumor cells is restricted by heparin through neutralization of cationic mediators, inhibition of heparanase, and adhesion molecules. Recent discoveries have meant that heparin is capable of targeting L- and P-selectin & integrin activity, as well as preventing cancer progression.

Key Future Prospects of Peptide and Heparin Market for Forecast Period 2017-2026

Hospital pharmacies are expected to remain the dominant distribution channel for peptide and heparin. Revenues from sales of peptide and heparin in hospital pharmacies are anticipated to remain considerably larger than those from retail pharmacies and online pharmacies combined.
On the basis of indication, revenues from sales of peptide and heparin for cancer treatment are projected to account for the largest market share by 2026-end. Cardiovascular and metabolic disorder indication will also remain remunerative in the market. Sales of peptide and heparin for central nervous systems indication are expected to register the fastest expansion through 2026.
Oral route of administration will remain preferred for peptide and heparin, with revenues estimated to surpass US$ 15,000 Mn by 2026-end. However, sales of peptide and heparin with intravenous route of administration will register a comparatively faster growth through 2026.
Liraglutide is expected to remain the most lucrative product in the market, followed by bortezomib and goserelin. Liraglutide sales will exhibit the highest CAGR through 2026. In addition, sales of sodium heparin, lithium heparin and exenatide are projected to register a parallel growth through 2026.
Asia-Pacific excluding Japan (APEJ) will continue to be the largest market for peptide and heparin, in terms of revenues. The markets in Europe and North America will also remain lucrative, however revenues from these regions will remain significantly lower than those from APEJ.

Browse Full Report with TOC @ https://www.factmr.com/report/378/peptides-heparin-market

APEJ to Remain Most Remunerative Market for Peptide and Heparin

There has been a growing demand for new oral anticoagulants having better efficacy and safety profiles in Asia-Pacific excluding Japan (APEJ). Side effects related to heparin products, including complications of bleeding and heparin-induced thrombocytopenia has resulted into robust adoption of oral anticoagulants in the region. In addition, rising incidence of cancer, metabolic disorders, and hepatitis, along with advancements in peptide synthesis technology and rapid demand for various peptide therapies in the region are expected to drive the growth in APEJ. APEJ will remain the most remunerative market for peptide and heparin.

Liraglutide and ammonium heparin are expected to remain fast-expanding products in the market. In addition, sales of exenatide, lithium heparin, and sodium heparin will register a similar CAGR through 2026.

Competition Tracking

The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors. These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas. Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future. Key market participants identified by the report include Baxter, Celsus, Biofer S.p.A,, Hemmo Pharma, AmbioPharm, Inc., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., Bachem, Abbott Laboratories, Pfizer Inc., Aspen, Leo Pharma, Teva, Takeda, Sanofi, Novo Nordisk, and Eli Lilly.

Buy Now! @ https://www.factmr.com/checkout/378/S

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare Market Research Reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick